Tag: substantially
How Concerned Should Traders Be Over China’s Stock Market?
Over the last week, Chinese stocks have fallen dramatically. Of course, other markets have had substantial drops over-generalized risk-off moves around the war in Ukraine. The drama of the war has overshadowed a lot of financial markets. The situation in China could have been dismissed as another manifestation of the consequences of geopolitics. However, China […]
The post How Concerned Should Traders Be Over China’s Stock Market? appeared first on Orbex Forex Trading Blog.
Sabrent Rocket 4 Plus NVMe SSD review: Fast on PCIe 4, fast on PCIe 3
At a GlanceExpert's Rating
Pros
- Excellent performance
- Exceptional sustained writes from the 2TB version
- Nice-looking copper color scheme
Cons
- 1TB version ran out of cache before the end of our 450GB write
Our Verdict
This drive is a worthy competitor to Samsung's 980 Pro, at least in the 2TB version. The 1TB will run out of juice on very long writes, something the 980 Pro won't do. Regardless, for the price, an excellent SSD.
Best Prices Today
Sabrent must've read some of my articles and discovered my love of the color copper. The heat-spreader and the metal carrying case for the brand spanking new Rocket 4 Plus PCIe 4 NMVe SSD feature the color in copious amounts. I like it. Even if copper leaves you flat, the drive's stellar performance will grab your attention—it bested the Samsung 980 Pro in many tests. This is one of the best SSDs around.
Editor's note: This review originally published on December 21, 2020. As of late January 2022, Sabrent has upgraded the NAND in the Rocket 4 Plus to Micron's B47, which has increased its sustained throughput substantially in our follow-up testing in March. As of this addendum, it's the sixth fastest NVMe SSD we've tested under CrystalDiskMark, and the second fastest drive in our 48GB transfer tests, up from 8th place.
Specs and pricing
The NVMe SSDs we review all use the M.2 connector, and are 22 mm wide by 80 mm long (2280). The Rocket 4 Plus is an x4 PCIe 4.0 device featuring a Phison PS5018-E18 controller and 96-layer, Micron TLC NAND. Sabrent promises not to change to slower components, as has happened with a couple of SSD vendors recently. There's also 2MB of DRAM cache. NAND is treated as SLC for secondary caching to the tune of 25 percent.
Beyond that, the drive is enveloped in coppery goodness (the label) and is available in two flavors: 1TB ($160 on Amazon) and 2TB ($310 on Amazon). A 500GB model exists for $90 but can be hard to fine online, while a 4TB flavor costs $750.
The drives carry a 5-year warranty, and are rated for 350TBW per 500GB of capacity. TBW is the number or terabytes that may be written before the drive warranty lapses. It's quite likely capable of writing more, but that's the company's cut-off point for replacement. Most users are unlikely to come close to that in a decade.
Performance
All that coppery goodness would mean nothing if the Rocket 4 Plus didn't haul the freight. The 2TB version I tested delivers. The Rocket 4 Plus's CrystalDiskMark 6 sustained throughput numbers are impressive indeed, trading first place between writing and reading with the Samsung 980 Pro.
The Rocket 4 Plus couldn't quite match the 980 Pro's overall real world performance in our 48GB transfer tests, but it took a solid second place.
CrystalDiskMark's 4K tests showed another story—the Rocket 4 Plus lagged significantly.
Where the 2TB Rocket 4 Plus really rocked was in our 450GB sustained write tests. Note however, that the 980 Pro Samsung sent me was only a 1TB model. Though it's not shown in the charts, the 1TB version dropped to around 675MBps (PCIe 3) at around the 350GB mark in the copy and took 386 seconds, compared to the 2TB version's 250 seconds on PCIe 3 and 209 seconds over PCIe 4. Yes, cache makes a difference.
I should also mention that in general, it's never a good idea to run an SSD close to capacity. Write speeds will slow down tremendously without NAND available as cache. Always overbuy in terms of capacity.
The PCIe 3 tests utilized Windows 10 64-bit running on a Core i7-5820K/Asus X99 Deluxe system with four 16GB Kingston 2666MHz DDR4 modules, a Zotac (NVidia) GT 710 1GB x2 PCIe graphics card, and an Asmedia ASM2142 USB 3.1 card. It also contains a Gigabyte GC-Alpine Thunderbolt 3 card, and Softperfect Ramdisk 3.4.6 for the 48GB read and write tests.
The PCIe 4 testing was done on an MSI MEG X570 motherboard socketing an AMD Ryzen 7 3700X 8-core CPU, using the same Kingston DRAM, cards, and software. All testing is performed on an empty, or nearly empty drive. Performance will decrease as the drive fills up.
A nice buy at 2TB
Though there's room for improvement in small- and 4K file performance, there's little else to complain about with the Sabrent Rocket 4 Plus in its 2TB incarnation. That it can wrestle at all with the 980 Pro at this price point is a feather in Sabrent's (and Phison's) cap.
Sisram Medical Ltd Announces 2021 Record Annual Results
FINANCIAL HIGHLIGHTS
-- Revenue for the year ended December 31, 2021 was US$294.3 million, increased by 81.6% as compared to the revenue for the previous year.
-- Profit for the year ended December 31, 2021 was US$32.5 million, increased by 121.5% as compared to that for the previous year.
-- Net cash flows from operating activities for the year ended December 31, 2021 was US$32.4 million, increased by 25.8% as compared to that for the previous year.
-- Significant growth in all regions, mainly in North America and APAC. Revenue in North America for the year ended December 31, 2021 was US$112.0 million, increased by 105.8% as compared to that for the previous year. Revenue in APAC for the year ended December 31, 2021 was US$85.2 million, increased by 95.3% as compared to that for the previous year.
BUSINESS HIGHLIGHTS
-- R&D investments increased by 42.3% YoY to US$15.6 million with 2 new products launched: "Alma Duo" and "Alma PrimeX".
-- Continued the development of two new business lines - (i) Copulla - a new, innovative digital dentistry service; (ii) LMNT, a personal care brand, now launching a light-based skin rejuvenation home use device.
-- The Group entered into a sub-license agreement with Fosun Industrial for the commercialization of "RT002" Injectable, the new generation of neurotoxins for medical aesthetics use. The Group's existing injectables distribution operation, registered a revenue growth of 50.1% year over year.
-- The Group entered into an investment agreement at the amount of RMB 2.6 million for the establishment of Tianjin Xingsiyi, a research & development, technical services and supply operation for silk fibroin-sodium injectables and facial implant thread products.
-- The Group has acquired the entire share capital of Shanghai Foshion Medical System to further enhance its dental business line.
-- The Group purchased the remaining 40% equity interest in its Israeli distributor, Nova Medical. Upon completion, Nova Medical is a wholly-owned subsidiary of the Company, rebranded as Alma Israel.
FINAL DIVIDEND
-- The Board has resolved to declare a final dividend of HK$0.157 (inclusive of tax) per Share for the year ended December 31, 2021.
Business Growth Projection for 2022
Based on an increase in the demand for the Company's products and the backlog of orders as of December 31, 2021, barring any unforeseen circumstances or material change in market conditions, the Group expects to record a significant growth in revenue of over 35.0% in the first half of 2022 as compared to the revenue recorded in the corresponding period in 2021.
Record results, strong subsidiaries performance, overall geographic performance uptake, continued investments in R&D and strong business development momentum In 2021, Sisram's established global sales and distribution network recorded a total revenue of US$294.3 million for the Reporting Period, representing an increase of 81.6% when compared to 2020. All regions revenue increased substantially during the Reporting Period with North America demonstrating an increase of 105.8%, Asia Pacific with an increase of 95.3%, Latin America with an increase of 76.3%, Europe with an increase of 49.7% and Middle East & Africa with an increase of 45.2%.
The gross profit increased from US$90.3 million in 2020 to US$166.9 million in 2021, representing an increase of US$76.6 million. The gross profit margin in 2021 amounted to 56.7%, representing an increase of 1% compared to 55.7% in 2020. The establishment of direct operation offices in chosen territories has enabled the Company to shorten the supply chain, increase the average selling price, gain a higher brand visibility and ensure consistency among the communications with the target clientele. During 2021, revenue derived from direct sales has surpassed revenue derived from distributors with 62.0% attributed to the former and 38.0% to the latter.
For the Reporting Period, the Group recorded an adjusted net profit of US$40.3 million representing an increase of 100.0% when compared with the corresponding period of 2020. The adjusted net profit margin for the Reporting Period was 13.7%. The net cash flow from operating activities amounted to US$32.4 million, representing an increase of 25.8% when compared to 2020.
In 2021, Sisram continued its substantial R&D efforts, with 13% of corporate employees being R&D specialists. During the Reporting Period, R&D expense increased by 42.3% to US$15.6 million from US$11.0 million for the corresponding period in 2020. During the Reporting Period, the Group launched 2 new products, "Alma Duo" and "Alma PrimeX", as well as expanded two business lines, "Copulla" - a new, innovative digital dentistry service, and "LMNT", a personal care brand, now launching a light-based skin rejuvenation home use device.
Continued Investments in Digital Transformation and Production Ramp-up
In 2021, Sisram continued the development of its digital core architecture with vast investments in Information Systems and Digitalization, encompassing traditional ERP and CRM modules, IoT solutions for professional capital equipment, marketing automation and consumer access. Over the past 3 years (2019-2021), Sisram invested more than US$6.5 million in information systems, upgrading its ERP and CRM infrastructure, migrating to cloud-based systems to serve the entire growing and diverse eco-system and implementing new digital tools for Internal organization management, external engagement mechanisms between the organization and the market and cyber security.
On the operational front, Sisram focused on addressing the pandemic effect by investing in production ramp-up to accommodate the growing global demand and improve quality performances KPI's such as FPY (First Pass Yield) and new platforms critical failure.
A Never-before-seen Synergistic Ecosystem Composed of 4 Pillars
Sisram's Wellness Group is a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more.
As of 2021 Sisram is operating 4 business lines. The Medical Aesthetics business line, led by Alma, registered a revenue increase of 73.4%. The Injectables business line registered a revenue increase of 50.1% year over year. In 2021, Sisram integrated the activity of Shanghai Foshion Medical System into Sisram, while developing Copulla's digital dentistry service. The Personal Care business line, LMNT by Sisram Medical, is a home-use brand, immersing the essence of wellness into consumers' daily routine.
Looking forward, Mr. Liu Yi, Chairman and Executive Director of Sisram, said: "As a core member of Fosun Pharma's medical device sector, as well as the core platform of Fosun's ecosystem, we have always insisted on customer-centric philosophy and focused on technology and innovation, to continuously improve our product power and competitiveness to respond to the rapid development of the industry. In 2022, based on our charted st rategy, we will continue to promote Sisram's ecosystem, and steadily expand the product portfolio and ecological interoperability between Sisram's ecosystem, Fosun Pharma's medical device sector, and even Fosun's greater ecosystem, so as to provide customers with advanced technologies and products through the enhancement of technological applications. We will also promote the sustainable and sound development of the industry by improving clinical applications. In addition, we shall meet the market demand of the aesthetic industry through our diversified product portfolio and market strategy."
Mr. Lior Dayan, CEO of Sisram and Alma, said: "The Group's efforts during 2022 will strategically focus on expanding direct operation in strategic markets to secure market access for both professional and consumer clientele, improve digital infrastructure and tools, drive awareness and preference to our global consumer brand and leverage it to globally introduce new products and services."
About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board.
Sisram Medical - Enhancing Quality of Life
http://www.sisram-medical.com
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding
Latest Intelligence
